한글목차

세계의 타크로리무스 시장은 2025-2033년 연평균 성장률(CAGR) 5.91%로 성장할 것으로 예측되어 현저한 확대가 전망되고 있습니다. 시장 분석에 따르면 시장 규모는 2024년 75억 9,000만 달러에서 2033년 말까지 127억 2,000만 달러에 이를 것으로 예측됩니다.

세계의 타크로리무스 시장은 장기 이식이나 자가면역질환 관리에 있어서 면역억제제로서의 중요한 역할에 견인되어 꾸준히 성장할 것으로 보입니다. 서방형 제형 및 국소 적용제와 같은 제형의 진보는 환자의 컴플라이언스 및 치료 성적을 향상시킵니다. 향후 개발은 바이오시밀러, 약리 유전체학에 기초한 개별화 투여, 부작용을 최소화하는 신규 전달 시스템 등에 초점이 맞추어질 예정입니다.

또한 장기 이식 증가 및 자가 면역 질환 증가로 환자 수가 확대되고 있습니다. 규제 당국의 승인과 특허의 해지가 시장 역학에 영향을 미치고 있습니다. 치료제 모니터링을 위한 디지털 건강 도구의 통합은 치료의 정확성을 향상시킵니다. 면역억제 치료의 진보에 따라 타크로리무스 시장은 앞으로도 기술 혁신을 계속하고 보다 안전하고 효과적이며 이용하기 쉬운 치료 옵션을 제공해 나갈 것입니다.

목차

제1장 서문

제2장 주요 요약

• 시장의 하이라이트
• 세계 시장 현황

제3장 타크로리무스 : 산업 분석

• 서문 : 시장 역학
• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 업계 동향
• Porter's Five Forces 분석
• 시장 매력 분석

제4장 밸류체인 분석

• 밸류체인 분석
• 원재료 분석
  • 원재료 리스트
  • 원재료 제조업체 리스트
  • 주요 원재료의 가격 동향
• 잠재적 구매자 목록
• 마케팅 채널
  • 직접 마케팅
  • 간접 마케팅
  • 마케팅 채널 발전 동향

제5장 세계의 타크로리무스 시장 분석 : 제품 유형별

• 개요 : 제품 유형별
• 과거 및 예측 데이터 분석 : 제품 유형별
• 주사제
• 정제 및 캡슐
• 연고제
• 과립제

제6장 세계의 타크로리무스 시장 분석 : 용도별

• 개요 : 용도별
• 과거 및 예측 데이터 분석 : 용도별
• 피부염
• 면역억제
• 기타 용도

제7장 세계의 타크로리무스 시장 분석 : 최종 용도별

• 개요 : 최종 용도별
• 과거 및 예측 데이터 분석 : 최종 용도별
• 병원
• 전문 클리닉
• 기타 최종 사용자

제8장 세계의 타크로리무스 시장 분석 : 지역별

• 지역별 전망
• 서문
• 북미의 매출 분석
  • 개요, 분석 및 예측
  • 북미 : 부문별
  • 북미 국가별
  • 미국
  • 캐나다
  • 멕시코
• 유럽의 매출 분석
  • 개요, 분석 및 예측
  • 유럽 : 부문별
  • 유럽 국가별
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양의 매출 분석
  • 개요, 분석 및 예측
  • 아시아태평양 : 부문별
  • 아시아태평양 국가별
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주
  • 동남아시아
  • 기타 아시아태평양
• 라틴아메리카의 매출 분석
  • 개요, 분석 및 예측
  • 라틴아메리카 : 부문별
  • 라틴아메리카 국가별
  • 브라질
  • 아르헨티나
  • 페루
  • 칠레
  • 기타 라틴아메리카
• 중동 및 아프리카의 매출 분석
  • 개요, 분석 및 예측
  • 중동 및 아프리카 : 부문별
  • 중동 및 아프리카 국가별 일람
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 남아프리카
  • 기타 중동 및 아프리카

제9장 타크로리무스 기업 경쟁 구도

• 타크로리무스 시장 경쟁
• 제휴, 협력 및 합의
• 합병 및 인수
• 신제품 출시
• 기타 개발

제10장 기업 프로파일

• 주요 기업의 시장 점유율 분석
• 시장 집중도
• Abbott Laboratories
• Astellas Pharma Inc.
• Biocon Ltd.
• F. Hoffmann-La Roche Ltd.
• Glenmark Pharmaceuticals Ltd.
• GSK Plc
• Lupin Pharmaceuticals Ltd.
• Novartis
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Viatris Inc

영문목차

Global Tacrolimus Market is anticipated to experience remarkable expansion, with a projected Compound Annual Growth Rate (CAGR) of 5.91% from 2025 to 2033. According to the market analysis, the market size is forecasted to reach USD 12.72 Billion by the end of 2033, up from USD 7.59 Billion in 2024.

The global tacrolimus market is set for steady growth driven by its critical role as an immunosuppressant in organ transplantation and autoimmune disease management. Advances in formulation, including extended-release and topical applications, are improving patient compliance and therapeutic outcomes. Future developments will focus on biosimilars, personalized dosing guided by pharmacogenomics, and novel delivery systems to minimize side effects.

Additionally, increasing organ transplant procedures and rising prevalence of autoimmune disorders are expanding patient populations. Regulatory approvals and patent expirations are influencing market dynamics. The integration of digital health tools for therapeutic drug monitoring is enhancing treatment precision. As immunosuppressive therapy advances, the tacrolimus market will continue to innovate, delivering safer, effective, and accessible treatment options.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Tacrolimus market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Injections
• Tablets And Capsules
• Ointments
• Granules

By Application

• Dermatitis
• Immunosuppression
• Other Applications

By End-Use

• Hospitals
• Specialty Clinics
• Other End-Users
• List of Companies Profiled in the report
• Abbott Laboratories, Astellas Pharma Inc., Biocon Ltd., F. Hoffmann-La Roche Ltd., Glenmark Pharmaceuticals Ltd., GSK plc, Lupin Pharmaceuticals Ltd., Novartis, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. TACROLIMUS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By End-Use
  • 3.7.4 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL TACROLIMUS MARKET ANALYSIS BY PRODUCT TYPE

• 5.1. Overview By Product Type
• 5.2. Historical and Forecast Data Analysis By Product Type
• 5.3. Injections Historic and Forecast Sales By Regions
• 5.4. Tablets And Capsules Historic and Forecast Sales By Regions
• 5.5. Ointments Historic and Forecast Sales By Regions
• 5.6. Granules Historic and Forecast Sales By Regions

6. GLOBAL TACROLIMUS MARKET ANALYSIS BY APPLICATION

• 6.1. Overview By Application
• 6.2. Historical and Forecast Data Analysis By Application
• 6.3. Dermatitis Historic and Forecast Sales By Regions
• 6.4. Immunosuppression Historic and Forecast Sales By Regions
• 6.5. Other Applications Historic and Forecast Sales By Regions

7. GLOBAL TACROLIMUS MARKET ANALYSIS BY END-USE

• 7.1. Overview By End-Use
• 7.2. Historical and Forecast Data Analysis By End-Use
• 7.3. Hospitals Historic and Forecast Sales By Regions
• 7.4. Specialty Clinics Historic and Forecast Sales By Regions
• 7.5. Other End-Users Historic and Forecast Sales By Regions

8. GLOBAL TACROLIMUS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE TACROLIMUS COMPANIES

• 9.1. Tacrolimus Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF TACROLIMUS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Abbott Laboratories
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Astellas Pharma Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Biocon Ltd.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. F. Hoffmann-La Roche Ltd.
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Glenmark Pharmaceuticals Ltd.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. GSK Plc
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Lupin Pharmaceuticals Ltd.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Novartis
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Pfizer Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Takeda Pharmaceutical Company Limited
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Viatris Inc
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies